Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
Primary Hyperparathyroidism
Type
Interventional
Phase
Not Applicable
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Parallel AssignmentMasking: Single (Outcomes Assessor)Primary Purpose: Screening

Participation Requirements

Age
Between 18 years and 65 years
Gender
Both males and females

Description

Parathyroid hormone, released from the parathyroid gland, plays an important role in keeping the ionized calcium in between the reference values in body. Precise control of ionized calcium is particularly necessary to ensure the optimal function of physiological processes such as providing intracell...

Parathyroid hormone, released from the parathyroid gland, plays an important role in keeping the ionized calcium in between the reference values in body. Precise control of ionized calcium is particularly necessary to ensure the optimal function of physiological processes such as providing intracellular signaling, performing neuromuscular functions and bone metabolism. When there is a decrease in the level of ionized calcium in the systemic circulation due to any reason, increased calcium concentration is maintained as a result of the increased absorption of calcium from the kidneys, bones and intestines into the blood via increased parathyroid hormone. An error caused by any of the components in this regulatory system may cause excessive parathyroid hormone release, causing primary, secondary or tertiary hyperparathyroidism. Primary hyperparathyroidism is a common endocrinological disorder, which is characterized by excessive release of parathyroid hormone, resulting in a defect in the regulation of calcium metabolism. Primary Hyperparathyroidism is the third most common endocrine disease and is the most common cause of hypercalcemia. Today, Primary Hyperparathyroidism is approximately 0.25-0.66% of the population and it is seen as 3: 1 times more common in women than men. While the incidence of the disease increases with age, it increases dramatically after 50 years of age. The clinical presentation of Primary Hyperparathyroidism ranges from asymptomatic disease to the classical symptomatic disease of renal and / or musculoskeletal complications. Low plasma 25 Hydroxyvitamin D level; bone mineral density, muscle strength, preservation of postural stability and functional performance of the musculoskeletal functions such as disruption caused by the person's walking and balance activities are adversely affected.In addition, fatigue, pain, and body mass index, as a result of the increase in the functional capacity of the person is seriously reduced quality of life and psychosocial status is adversely affected. Although there are studies related to bone mineral density, muscle strength and function, instability, fatigue, etc., which are secondary to PHPT and cause a significant decrease in functional capacity, there is no study to investigate the effect of M. quadriceps Femoris ,which has a key role in the evaluation of functional capacity, muscle fatigue on the gait and balance parameters in the pre and post-treatment period in the literature. The aim of this case-control study is to investigate the effect of Quadriceps Femoris muscle fatigue protocol on gait, gait symmetry and balance parameters before and after parathyroidectomy in patients Primary Hyperparathyroidism and to compare that parameters of these individuals with healthy controls with similar demographic characteristics that included in the control group.

Tracking Information

NCT #
NCT03713671
Collaborators
  • Hacettepe University
  • Ankara Education and Research Hospital
Investigators
Principal Investigator: Melek M. ERDEM Tayyip Erdogan University Training and Research Hospital Study Director: Gonul KOC, MD Ankara Education and Research Hospital Study Director: Semra TOPUZ, Assoc. Prof. Hacettepe University Study Chair: Mikail K. DEMIREL, MD Ankara Education and Research Hospital Study Chair: Isilay TASKALDIRAN, MD Ankara Education and Research Hospital Study Chair: Cavit CULHA, Assoc. Prof. Ankara Education and Research Hospital